Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Zentalis Pharmaceuticals, Inc. (ZNTL)

20.39   -0.1 (-0.49%) 09-27 11:21
Open: 20.66 Pre. Close: 20.49
High: 20.83 Low: 20.29
Volume: 99,870 Market Cap: 1,440(M)

Technical analysis

as of: 2023-09-27 10:50:40 AM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 28.89     One year: 32.13
Support: Support1: 20.25    Support2: 16.85
Resistance: Resistance1: 24.73    Resistance2: 27.51
Pivot: 22.9
Moving Average: MA(5): 21     MA(20): 23.73
MA(100): 25.9     MA(250): 22.8
MACD: MACD(12,26): -1.4     Signal(9): -1.1
Stochastic oscillator: %K(14,3): 3.1     %D(3): 3.3
RSI: RSI(14): 21.9
52-week: High: 31.45  Low: 15.55
Average Vol(K): 3-Month: 502 (K)  10-Days: 865 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ZNTL ] has closed above bottom band by 12.0%. Bollinger Bands are 40.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 21.2 - 21.34 21.34 - 21.46
Low: 19.87 - 20.07 20.07 - 20.22
Close: 20.22 - 20.48 20.48 - 20.69

Company Description

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

Headline News

Tue, 26 Sep 2023
Zentalis Pharmaceuticals Receives Favorable Ratings and Positive ... - Best Stocks

Tue, 26 Sep 2023
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average ... - MarketBeat

Thu, 21 Sep 2023
Is Zentalis Pharmaceuticals Inc (ZNTL) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Mon, 18 Sep 2023
Oversold Conditions For Zentalis Pharmaceuticals (ZNTL) - Nasdaq

Tue, 05 Sep 2023
Dynamic Changes in Ownership: ExodusPoint Capital Management ... - Best Stocks

Fri, 01 Sep 2023
Should You Accumulate Zentalis Pharmaceuticals Inc (ZNTL) in Biotechnology Industry? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 71 (M)
Shares Float 54 (M)
% Held by Insiders 2.7 (%)
% Held by Institutions 102 (%)
Shares Short 12,000 (K)
Shares Short P.Month 13,320 (K)

Stock Financials

EPS -4.77
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.4
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -23.6
Return on Equity (ttm) -57.3
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.16
Qtrly Earnings Growth 0
Operating Cash Flow -199 (M)
Levered Free Cash Flow -90 (M)

Stock Valuations

PE Ratio -4.29
PEG Ratio 0
Price to Book value 2.75
Price to Sales 0
Price to Cash Flow -7.23

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.